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Background. Oleic acid (OA) stimulates vascular smooth muscle cell (VSMC) proliferation and migration. The precise
mechanism is still unclear. We sought to investigate the effects of peroxisome proliferator-activated receptor gamma (PPARc)
coactivator-1 alpha (PGC-1a) on OA-induced VSMC proliferation and migration. Principal Findings. Oleate and palmitate, the
most abundant monounsaturated fatty acid and saturated fatty acid in plasma, respectively, differently affect the mRNA and
protein levels of PGC-1a in VSMCs. OA treatment resulted in a reduction of PGC-1a expression, which may be responsible for
the increase in VSMC proliferation and migration caused by this fatty acid. In fact, overexpression of PGC-1a prevented OA-
induced VSMC proliferation and migration while suppression of PGC-1a by siRNA enhanced the effects of OA. In contrast,
palmitic acid (PA) treatment led to opposite effects. This saturated fatty acid induced PGC-1a expression and prevented OA-
induced VSMC proliferation and migration. Mechanistic study demonstrated that the effects of PGC-1a on VSMC proliferation
and migration result from its capacity to prevent ERK phosphorylation. Conclusions. OA and PA regulate PGC-1a expression in
VSMCs differentially. OA stimulates VSMC proliferation and migration via suppression of PGC-1a expression while PA reverses
the effects of OA by inducing PGC-1a expression. Upregulation of PGC-1a in VSMCs provides a potential novel strategy in
preventing atherosclerosis.
Citation: Zhang Y, Liu C, Zhu L, Jiang X, Chen X, et al (2007) PGC-1a Inhibits Oleic Acid Induced Proliferation and Migration of Rat Vascular Smooth
Muscle Cells. PLoS ONE 2(11): e1137. doi:10.1371/journal.pone.0001137
INTRODUCTION
Pathogenic development of atherosclerosis involves a complex
series of events [1], of which abnormal proliferation and migration
of vascular smooth muscle cells (VSMCs) contribute significantly
to the progression of atherosclerosis [2]. One independent risk
factor for atherosclerosis is obesity [3,4]. Obese hypertensive
elevates plasma free fatty acids (FFAs) [5], particularly oleic acid
(OA) [6], which promotes VSMCs from contractile to synthetic
type, stimulates VSMC proliferation and migration to suben-
dothelium, and contributes to the formation of organized
atherosclerotic plaque [7]. OA, the most abundant unsaturated
fatty acid in plasma [8], induces VSMC proliferation and
migration by direct induction of extracellular signal-regulated
kinase (ERK)-dependent mitogenic response [6,9–11].
Recent studies demonstrated that thiazolidinediones (TZDs),
the ligands for nuclear receptor peroxisome proliferator-activated
receptor gamma (PPARc), improved cardiovascular risk factors via
exerting direct effects on vascular cells, for example, inhibition of
VSMC proliferation and migration [12,13]. It has been shown
that TZDs inhibit key steps in the ERK/MAPK pathway, block
the events that are critical for the re-entry of quiescent VSMCs
into cell cycle, thus retard serum-induced growth of cultured
arterial VSMCs and PDGF-BB-directed migration of VSMCs
[13–15].
PPARc coactivator-1 alpha (PGC-1a) is originally identified as
a transcriptional coactivator of PPARc [16]. Recent studies show
that PGC-1a regulates the activity of several nuclear receptors and
other transcriptional factors [17]. The basic biochemical function
of PGC-1a is the regulation of mitochondrial biogenesis [18].
PGC-1a is widely expressed, including brown fat, skeletal muscle,
liver, heart, kidney and brain [16,19,20]. PGC-1a plays important
roles in many tissues, including the regulation of adaptive
thermogenesis in brown fat and muscle [16], of muscle fiber-type
switching in muscle [21], of gluconeogenesis in liver [22], and of
insulin secretion in islets [23]. There are also large body of work to
study regulation of PGC-1a expression in different tissues [24,25].
It has been reported that elevated FFAs regulate expression of
PGC-1a [26,27], and certain FFAs affect PGC-1a expression
differently [28–31]. Recently, Hondares et al have reported an
autoregulatory loop between PGC-1a and PPARc in adipocytes
[32]. However, there is no report of regulation and function of
PGC-1a in VSMCs.
In the present study, we examined the effects of FFAs (OA and/
or palmitic acid PA) on PGC-1a expression in VSMCs. We also
assessed the possible role of PGC-1a in OA-induced VSMC
proliferation and migration. We found that OA and PA had an
opposite role in regulating PGC-1a expression in rat VSMCs and
PGC-1a inhibited OA-induced VSMC proliferation and migra-
tion via the inhibition of ERK phosphorylation.
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OA stimulated VSMC proliferation and migration
which is associated with decreased PGC-1a
expression
OA was suggested to be the acting component of FFAs inducing
VSMC proliferation and migration [6,9–11]. In this study, we
used 0.4 mmol/L OA to stimulate cultured rat VSMCs and
detected changes of cell proliferation and migration. MTT assay
showed that OA increased VSMC proliferation by 2-fold after
24 h stimulation (p,0.001 versus control, Fig. 1A). Direct cell
counting confirmed that the increment in cell number (seeded at
1.5610
5 cells/well) was greater in OA treated VSMCs
(4.9760.23610
4 versus 2.4560.16610
4 cells/well, p,0.001
versus control, Fig. 1B). Directional migration of VSMC
monolayers after mechanical wounding was next performed, and
the data presented in Fig. 1C demonstrated that OA increased
VSMC migration by 2.5-fold (160.265.7 versus 63.863.5 mm,
p,0.001 versus control). Transwell chamber assay also showed
that OA-treated VSMCs migrated 2.8-fold faster than control cells
(282.6619.6 versus 99.4610.8, p,0.001, Fig. 1D).
As shown in Fig. 1E, VSMCs were treated with 0.4 mmol/L
OA, and then PGC-1a mRNA levels were detected at various
time. The time course was linear over 48 h, representing initial
decrease and increase thereafter, and PGC-1a mRNA level was
significantly decreased at 12h and 24h after OA administration
(p,0.01 versus control, Fig. 1E). VSMCs were also treated with
various concentrations of OA for 24 h and PGC-1a expressions
were examined by quantitative PCR and western blot. Results
showed that PGC-1a mRNA and protein expressions were dose-
dependently down-regulated by 0.2 mmol/L and 0.4 mmol/L
OA, and decreased to the lower level (mRNA level:53%, p,0.01
versus control, Fig. 1F; protein level: 68%, p,0.05 versus control,
Fig. 1G) at 0.4 mmol/L OA treatment.
Figure 1. OA-stimulated VSMC proliferation and migration is associated with decreased expression of PGC-1a. VSMCs were incubated with
0.4 mmol/L OA for 24 h before analysis. VSMC proliferation were determined by MTT assay (A) and direct cell counting (B). VSMC migration was
assessed by wound healing assay (C) and transwell analysis (D). The time course of 0.4 mmol/L OA effect on PGC-1a expression was linear over 48 h.
PGC-1a expression was quantified by quantitative PCR (E). VSMCs were treated with various concentrations of OA for 24 h. PGC-1a expression was
examined by quantitative PCR (E) and western blot (F). Data in VSMC proliferation and migration detections represent the means6SEM of 18
determinants from 3 independently prepared samples each with 6 measurements. Data in PGC-1a mRNA level detections are expressed as
means6SEM of five different experiments normalized to b-actin levels. Data in PGC-1a protein level detections are expressed as means6SEM of four
different experiments normalized to GAPDH levels. *P,0.05, **P,0.01, #P,0.001 vs. control.
doi:10.1371/journal.pone.0001137.g001
PGC-1a’s Role in VSMC Growth
PLoS ONE | www.plosone.org 2 November 2007 | Issue 11 | e1137Increased PGC-1a expression inhibits OA-induced
VSMC proliferation and migration
To investigate the role of PGC-1a in VSMC proliferation and
migration, we stimulated PGC-1a expression by transient trans-
fection with recombinant adenoviruses expressing PGC-1a/GFP
protein. 48 h infection of Ad-PGC-1a markedly increased PGC-1a
mRNA (over 5-fold, p,0.001 versus control, Fig. 2A) and protein
(over 2-fold, p,0.01/0.001 versus control, Fig. 2B) levels in both
quiescent and OA-stimulated VSMCs.
VSMC proliferation and migration were next analyzed by
overexpressing PGC-1a. As shown in Fig. 2C–2F, OA still
stimulated cell proliferation and migration in Ad-GFP infected
VSMCs, suggesting that adenovirus infection with GFP alone had
no effect on OA’s stimulation. However, when cells were transfected
with Ad-PGC-1a, which caused elevated PGC-1a expression,
VSMC proliferation and migration were significantly decreased
compared with control (Ad-GFP). MTT assay showed that VSMC
proliferation decreased to 40% (p,0.01 versus Ad-GFP, Fig. 2C).
Direct cell counting confirmed that the OA-induced increment in
cell number was less in Ad-PGC-1a transfected VSMCs
(2.0660.24610
4 versus 5.3260.29610
4 cells/well, P,0.001 versus
Ad-GFP, Fig. 2D). At one time, OA-induced migration decreased to
31% (48.566.7 versus 155.764.7 mm, P,0.001 versus Ad-GFP,
Fig. 2E). Transwell chamber assay also showed the number of
Figure 2. Effect of overexpressed PGC-1a on OA-induced VSMC proliferation and migration. VSMCs were treated with 48 h adenovirus infection,
then incubated with 0.4 mmol/L OA for 24 h. PGC-1a expression was analysised by quantitative PCR (A) and western blot (B). Effects of PGC-1a
overexpression on OA-induced VSMC proliferation were determined by MTT assay (C) and cell counting (D). Effects of PGC-1a overexpression on OA-
induced VSMC migration were determined by wound healing (E) and transwell analysis (F). Data in VSMC proliferation and migration detections
represent the means6SEM of 18 determinants from 3 independently prepared samples each with 6 measurements. Data in PGC-1a mRNA level
detections are expressed as means6SEM of five different experiments normalized to b-actin levels. Data in PGC-1a protein level detections are
expressed as means6SEM of four different experiments normalized to GAPDH levels. *P,0.05, **P,0.01, #P,0.001 vs. control or GFP group.
doi:10.1371/journal.pone.0001137.g002
PGC-1a’s Role in VSMC Growth
PLoS ONE | www.plosone.org 3 November 2007 | Issue 11 | e1137migrated cells was decreased in Ad-PGC-1a transfected VSMCs
(103.4614.0 versus 256.6616.9, P,0.001 versus Ad-GFP, Fig. 2F).
PGC-1a almost inhibited OA-induced VSMC proliferation and
migration to a quiescent level, but had no effect on quiescent
VSMCs where OA was absent (Fig. 2).
Suppression of PGC-1a by siRNA amplifies the
OA-induced VSMC proliferation and migration
To further test our hypothesis that exogenous PGC-1a inhibits
OA-induced VSMC proliferation and migration, we decreased
PGC-1a expression by siRNA interference. As shown in Fig. 3A
and 3B, siRNA S1 inhibited PGC-1a mRNA level by 80–88%
(p,0.01/0.001 versus control) and protein level by 70%–80%
(p,0.001 versus control) in both quiescent and OA-stimulated
VSMCs. In contrast to the effects of elevated PGC-1a, the
decrease of PGC-1a accelerated OA-induced VSMC proliferation
and migration. OA-stimulated proliferation increased by 1.6-fold
(p,0.001 versus N, Fig. 3C), and the cell number was greater in
siRNA S1 transfected VSMCs (9.7360.21610
4 versus
5.1760.14610
4 cells/well, P,0.001 versus N, Fig. 3D). OA-
induced directional migration increased by 1.8-fold (259.765.4
versus 143.665.7 mm, P,0.001 versus N, Fig. 3E), and the
number of migrated cells was greater in siRNA S1 transfected
VSMCs (515.6637.9 versus 298.4617.7, P,0.001 versus N,
Fig. 3F). All these results demonstrated that suppression of PGC-
1a amplified OA-induced VSMC proliferation and migration, but
also had no effect on quiescent VSMCs (Fig. 3).
Figure 3. Effect of suppressed PGC-1a expression on OA-induced VSMC proliferation and migration. VSMCs were transfected with siRNA S1 or the
negative control (siRNA N). The interference effect was assessed by quantitative PCR (A) and western blot (B). Effects of decreased PGC-1a on OA-
induced VSMC proliferation were determined by MTT assay (C) and cell counting (D). Effects of decreased PGC-1a on OA-induced VSMC migration
were determined by wound healing (E) and transwell analysis (F). Data in VSMC proliferation and migration detections represent the means6SEM of
18 determinants from 3 independently prepared samples each with 6 measurements. Data in PGC-1a mRNA level detections are expressed as
means6SEM of five different experiments normalized to b-actin levels. Data in PGC-1a protein level detections are expressed as means6SEM of four
different experiments normalized to GAPDH levels. **P,0.01, #P,0.001 vs. control or N group.
doi:10.1371/journal.pone.0001137.g003
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inhibits OA-induced VSMC proliferation and
migration
Palmitic acid (PA) is the most prevalent saturated FFA in
circulation [33]. In this study, we also examined the effects of
PA on VSMC growth and PGC-1a expression. In contrast to OA,
addition of 0.4 mmol/L PA to VSMCs for 24 h markedly
increased PGC-1a mRNA level by 3.2-fold (p,0.001 versus
control, Fig. 4A) and protein level by 2-fold (p,0.01 versus
control, Fig. 4B). So we used PA as an inducer of endogenous
PGC-1a and further examined PGC-1a’s functions in VSMCs.
As shown in Fig. 4C–4H, when OA and PA were mixed to
a final concentration of 0.4 mmol/L, PGC-1a expression was
Figure 4. Changes of PGC-1a expression and VSMC proliferation/migration in response to increased proportion of PA in fatty acid mixtures.
VSMCs were incubated with various FFAs for 24 h before analysis. Effects of PA on PGC-1a expression was determined by quantitative PCR (A) and
western blot analysis (B). Effects of increased PA on PGC-1a expression were determined by quantitative PCR (C). Effects of increased PA on OA-
induced VSMC proliferation were determined by MTT assay (D) and cell counting (E). Effects of increased PA on OA-induced VSMC migration were
determined by wound healing (F) and transwell analysis (G,H). Data in VSMC proliferation and migration detections represent the means6SEM of 18
determinants from 3 independently prepared samples each with 6 measurements. Data in PGC-1a mRNA level detections are expressed as
means6SEM of five different experiments normalized to b-actin levels. Data in PGC-1a protein level detections are expressed as means6SEM of four
different experiments normalized to GAPDH levels. *P,0.05, **P,0.01, #P,0.001 vs. control
doi:10.1371/journal.pone.0001137.g004
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fraction, and consequently led to the inhibition of OA-induced
VSMC proliferation and migration. 1:1 molar ratio of OA:PA
moderately increased PGC-1a expression (Fig. 4C), but still
stimulated VSMC proliferation and migration, although the
stimulation was depressed compared with the effects of OA alone
(Fig. 4D–4H); Increasing PA fraction in OA/PA mixture with
ratio 1:2 (0.133 mmol/L OA to 0.267 mmol/L PA) stimulated
higher endogenous PGC-1a expression (Fig. 4C), and suppressed
VSMC proliferation and migration to a quiescent level (Fig. 4D–
4H). Please note that this quiescence was due to the increased
amount of PA, but not due to the decreased amount of OA,
because 0.133 mmol/L and 0.2 mmol/L OA still increased
VSMC proliferation and migration as well as 0.4 mmol/L OA
(Fig. 4D–4H).
Effect of PGC-1a inhibition on p-ERK activity in
response to OA
OA stimulated VSMC proliferation and migration through the
activation of MAPK ERK signaling [6,9–11]. To investigate
whether ERK is activated by OA in VSMCs, we performed
western blot analysis with a mouse monoclonal antibody that
recognized the phosphorylated ERK (p-ERK). PDGF-BB (Sigma)
and pharmacological ERK-MAPK inhibitor PD98059 (Cell
signal) were chosen as positive and negative controls of ERK
phosphorylation, respectively. VSMCs were made quiescent by
serum-starvation for 24 h and then stimulated with PDGF-BB
(100ng/ml) for 30 min, PD98059 (50uM) for 1 h before
stimulation with PDGF-BB, or 0.4 mmol/L OA for 24 h. Western
blot revealed the presence of p-ERK in VSMCs (Fig. 5). As shown
in Fig. 5A, low amounts of p-ERK were found in 24 h serum-
starved VSMCs. The level of p-ERK was significantly increased
by PDGF-BB (over 20-fold, p,0.001 versus control), and this
increase was inhibited 90% by PD98059 (p,0.001 versus PDGF
alone). 0.4 mmol/L OA also increased the phosphorylation of
ERK (over 10-fold, P,0.001 versus control) as well as PDGF-BB.
To study whether inhibitory effects of PGC-1a on VSMC
proliferation and migration were related to MAPK ERK pathway,
phosphorylation of ERK was also analyzed in VSMCs with
elevated PGC-1a. VSMCs treated with 48 h adenovirus infection
were incubated with 0.4 mmol/L OA for 24 h, and then p-ERK
was detected by western blot. Results showed that OA still
stimulated phosphorylation of ERK in Ad-GFP transfected
VSMCs, however, when cells were transfected with Ad-PGC-1a,
the phosphorylation of ERK decreased approximately 80%
(p,0.001 versus Ad-GFP, Fig. 5B), which almost reverted the
OA-induced phosphorylation of ERK, and accordingly inhibited
OA-induced VSMC proliferation and migration.
DISCUSSION
PGC-1a, an important transcriptional coactivator, plays a key role
in energy metabolism [16,17]. PGC-1a is closely related to FFA
metabolism, and its expression level changes in various tissues in
rodent models of metabolic disorders [17,25]. It has also reported
that various saturated, unsaturated, and trans fatty acids, including
monounsaturated (oleic acid, C18:1) and polyunsaturated (linoleic
acid, C18:2; EPA, C20:5; DHA, C22:6; and arachidonic acid, C20:4),
saturated fatty acids of varying chain length (C10:0 to C18:0), and
trans fatty acids such as elaidic acid (trans-C18:1) and trans-vaccenic
acid (trans-C18:1) which are abundantly present in hydrogenated
vegetable oil and dairy products, had no effect on the expression of
PGC-1a, except stearic acid (C18:0), induced PGC-1a mRNA 2.2-
fold in primary hepatocytes [28]. Staiger H et al reported that
PGC-1a expression was increased two- to three-fold by all
unsaturated fatty acids they tested, while, saturated fatty acids
did not modulate PGC-1a expression in human myotubes [29].
Figure 5. Effects of PGC-1a on OA-induced p-ERK activity in VSMCs. PDGF-BB and pharmacological ERK-MAPK inhibitor PD98059 were chosen as
positive and negative controls of ERK phosphorylation, respectively. VSMCs were made quiescent by serum-starvation for 24 h and then stimulated
with PDGF-BB (100 ng/ml) for 30 min, PD98059 (50 uM) for 1 h before stimulation with PDGF-BB (100 ng/mL), or 0.4 mmol/L OA for 2 h. Proteins
extracted following these treatments and phosphorylation of ERK was determined by western blot (A). VSMCs were also treated with 48 h adenovirus
infection and then incubated with 0.4 mmol/L OA for 24 h. Phosphorylation of ERK was also analyzed with elevated PGC-1a level by western blot (B).
Data were shown as the ratio of p-ERK/total ERK. The ratios of control were designated as 1.0. Individual data in this chart represent the mean6SEM
of 4 determinants. #P,0.001 vs. control or positive/negative group.
doi:10.1371/journal.pone.0001137.g005
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downregulated PGC-1a in myotubes [30,31]. In the present
study, we have found that OA inhibited, while PA stimulated
PGC-1a expression in VSMCs (Fig. 1 and Fig. 4). Taking together,
these results indicate that certain fatty acids regulate PGC-1a
expression in a tissue-autonomous manner, and it may be related
to the different physiological role of PGC-1a played in tissues.
Given the facts that PGC-1a played a key role in energy
metabolism and that elevated FFAs level is one of major risk
factors in many metabolic disorders, it is important to understand
the mechanism of FFA regulating PGC-1a expression. Coll T et al
described the MEK1/2 inhibitors PD98059 and U0126 prevented
PA-induced downregulation of PGC-1a in C2C12 myotubes [30].
Furthermore, nuclear factor- kappaB (NF-kB) activation was also
involved in palmitate-mediated PGC-1a downregulation [30].
Interestingly, Crunkhorn S et al have found that PA inhibiting
PGC-1a expression required p38 mitogen-activated protein kinase
activation in the same C2C12 myotubes [31]. In adipocytes,
Hondares E et al demonstrated that there is an autoregulatory loop
controls PGC-1a expression via PPARc coactivation [32]. We
have found that FFA (0.4 mmol/L, equimolar mixtures of OA and
PA) induced PPARc mRNA level in VSMCs, and downregulation
of PGC-1a retarded the FFA’s induction (Data not shown). Thus,
it is interesting to further study whether the autoregulatory loop of
PGC-1a-PPARc is also existed in VSMCs.
It is well established that OA induces VSMC proliferation [9]
and migration [11], plays a central role in obesity and high fatty
acids induced atherosclerosis [7]. In this study, we have found that
overexpression of PGC-1a by adenovirus infection blocked OA-
induced VSMC proliferation and migration (Fig. 2). In contrast,
suppression of PGC-1a expression by siRNA amplified the OA’s
effects on VSMCs (Fig. 3). Interestingly, PGC-1a had no effect on
quiescent VSMCs where OA was absent (Fig. 2 and Fig. 3).
Combined together, the results revealed that PGC-1a is an
important negative regulator for VSMC proliferation and migration
under pathophysiological conditions, such as OA stimultion. PA is
the most prevalent saturated FFA in circulation [33]. In contrast to
OA, PA markedly induced PGC-1a expression in VSMCs (Fig. 4B).
Decrease of OA/PA ratios caused dose-dependent stimulation of
PGC-1a expression and gradually reversed the OA’s effects on
VSMC proliferation and migration (Fig. 4C–4H). Furthermore,
downregulation of PGC-1a by RNAi blocked the effects of PA (Data
not shown). These results demonstrated the induction of endogenous
PGC-1a by PA also inhibited OA-induced VSMC proliferation and
migration, which further confirmed the negative role of PGC-1a in
VSMC growth. Of note, 1:1 molar ratio of OA/PA with a final
concentration of 0.4 mmol/L mimics the high fatty acid pathophys-
iological state [34,35]. It moderately increased PGC-1a expression
but still stimulated VSMC proliferation and migration, suggesting
that increase of PGC-1a by pathophysiological fatty acid maybe not
sufficient to retard OA-induced VSMC proliferation and migration.
The mechanism of OA-induced VSMC proliferation and
migration has been proposed based on several facts: 1, OA
directly induced mitogenesis in cultured VSMCs through in-
creasing ERK phosphorylation [6,9–11], an active form of ERK
(p-ERK), which in turn, promoted VSMC proliferation and
migration; 2, ERK1/2 was an upstream regulator in mitogenic
response and was activated by agonists for tyrosine kinase encoded
receptors and G protein-coupled receptors that initiated mitogen-
esis or cellular differentiation [36]; 3, ERKs mediated the effects of
these agonists by phosphorylating and regulating the activity of
a number of proteins and transcription factors, such as Elk-1 and
Ets-1 [36,37], which evoked c-Fos and MMP-9 [37,38], and
contributed to VSMC proliferation and migration, respectively. In
the present study, we demonstrated that OA markedly increased
phosphorylated ERK1/2 protein levels in VSMCs, whereas
overexpression of PGC-1a almost abolished this stimulation of
p-ERK (Fig. 5). These data indicate that PGC-1a inhibits OA-
induced p-ERK activity, consequently, inhibits VSMC prolifera-
tion and migration.
The mechanism by which fatty acids (OA and PA) affect PGC-
1a mRNA and protein levels, however, remains unknown.
Previous studies show that the PPAR family of proteins may be
involved in the process of development of atherosclerosis [39,40].
TZD, a PPARc ligand, inhibits VSMC proliferation and
migration through the activation of PPARc, which tends to inhibit
the expression of several genes involved in extracellular signal-
regulated kinase (ERK)-dependent mitogenic response, leading to
the inhibition of cell growth and, finally, cell migration [12–15].
Furthermore, Hondares E et al demonstrated that there is an
autoregulatory loop controls PGC-1a expression via PPARc
coactivation in adipocytes [32]. Given that PGC-1a acts as
a transcriptional coactivator for PPARc, it is very possible that the
inhibition of PGC-1a in OA-induced VSMC proliferation and
migration is PPARc dependent. In fact, we have found that
overexpression of PGC-1a induced PPARc mRNA expression in
quiescent VSMCs. Downregulation of PGC-1a retarded FFA
(0.4 mmol/L, equimolar mixtures of OA and PA) induced PPARc
mRNA level (Data not shown). It has been described that TZD
actives PPARc, arrests MAPK ERK pathway [39,40,12–15], thus,
prevents c-fos production which is required for S-phase entry
induced in VSMCs [41], and inhibit MMP-9 production which is
required in VSMC migration [42]. We have also found that PGC-
1a negatively regulate not only p-ERK but also c-fos/MMP-9
expressions in OA-stimulated VSMCs (Data not shown). Taking
together, PGC-1a increases PPARc expression, and negatively
regulates ERK MAPK pathway, consequently inhibits OA-
induced VSMC proliferation and migration. Moreover, PPARc
RNAi or antagonist should be used for assessing the precise
mechanism of PGC-1a affecting OA-induced VSMC proliferation
and migration in the PPARc-dependent manner in further study.
In summary, we demonstrated that OA and PA regulate PGC-
1a expression differently in VSMCs. OA stimulates VSMC
proliferation and migration via suppression of PGC-1a expression.
Upregulation of PGC-1a in VSMC could be a novel strategy of
treatment of atherosclerosis.
MATERIALS AND METHODS
Cell culture
Rat aortic VSMCs were isolated from the thoracic aortas of 3- to
4-week-old male Sprague-Dawley rats as described previously
[43]. Isolated VSMCs were cultured in DMEM (Gibco-Invitro-
gen, Carlsbad, USA) supplemented with 10% FCS (GBICO BRL,
Rockville, MD), 25 mmol/L HEPES (pH 7.4), penicillin (100 U/
mL), and streptomycin (100 mg/mL) at 37uC in a humidified
atmosphere of 95% air and 5% CO2. VSMCs were identified by
the characteristic ‘‘hill and valley’’ growth pattern and positive
immunocytochemical staining with a monoclonal antibody against
smooth muscle a-actin (Progen). Cells after the 4th to 8th passages
were used in experiments.
Adenovirus infection
Recombinant adenoviruses expressing PGC-1a-GFP (Green
Fluorescence Protein) protein and GFP alone were provided by
Dr. Dan Kelly (Washington University, Saint Louis, MO, USA).
Purified virus stocks were prepared through CsCl step gradient
centrifugation as described previously [44]. Cells were grown to
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with adenovirus at multiplicities of infection (moi) of 50. The
infection efficiency was determined by fluorescence intensity of
GFP. Cells were harvested for total RNA extraction after 48 h
infection.
siRNA interference
To knock down PGC-1a expression in VSMCs, three siRNA
sequences targeting different sites of rat PGC-1a cDNA were
designed and synthesized by Genesil (Wuhan, P.R. China),
including a control sequence which could not target PGC-1a
cDNA. siRNA was transfected into VSMCs using LipofectAmine
reagent (Gibco-Invitrogen) according to the manufacture’s man-
ual. 48 h after medium replacement, VSMCs were harvested for
total RNA isolation, and PGC-1a expression level was analyzed by
quantitative PCR. The sequence with the best interfering effect
(named S1) was selected. siRNA sequences were as follows: S1,
AAGACGGATTGCCCTCATTTG; S2, AAGAGCCGTCTC-
TACTTAAGA; S3, AAGCTTGCGCAGGTAACATGT; N (the
negative control sequence), AAGCTTCATAAGGCGCATAGC.
Fatty acid treatments on VSMCs
OA and PA (Sigma) were dissolved in ethanol as 50 mmol/L stock
solutions respectively, and were further diluted in DMEM medium
supplemented with 2% fatty acid free BSA (Sigma) to a final
concentration of 0.4 mmol/L. The 0.4 mmol/L OA/PA mixtures
with molar ratios of 1:1 and 1:2 were also prepared. FFAs were
applied to VSMCs for 24 h before analysis.
VSMC Proliferation Assays
The microculture tetrazolium (MTT) assay was used to detect
VSMC proliferation [45]. Cells seeded in 96-well plates (1610
4
cells/well) were cultured up to confluence, and the medium was
replaced by fresh serum-free medium. The cells were then treated
with adenovirus infection or siRNA interference for 48 h, followed
by 24 h fatty acids stimulation. At the end of this period, MTT
(0.2 mg/mL) was added to each well, and incubation proceeded
for 4 h at 37uC. Thereafter, the culture medium was removed and
the cells were solubilized in 100 mL DMSO. The extent of
reduction of MTT to formazan within cells was quantified
spectrophotometrically at 595 nm and taken as an indicator of
cell viability [45]. Cell counting analysis was used to confirm the
MTT analysis. VSMCs were seeded in 6-well plates (1.5610
5
cells/well) and treated in the same way. Cells were then
resuspended with 0.05% trypsin and 0.02% EDTA, and cell
numbers were determined by a hemocytometer.
VSMC migration assays
Migration assays were performed by 2 approaches: scratch wound
motility assay [46,47] and the modified Boyden chamber [48,49].
For the scratch wound motility assay, VSMCs were seeded in 6-
well plates (1.5610
5 cells/well) and grew to confluence. 24 h after
serum deprivation, VSMCs were treated with adenovirus infection
or siRNA interference for 48 h. Treated cells were then mounted
to a reusable template to create a standard wound (<3 mm),
followed by 24 h fatty acids treatment. Wound closure rates were
followed with a reference point in the field of the wound at the
bottom of the plate by direct microscopic visualization. The
procedure permitted photographing the identical spot each time.
The remaining cell-free area was determined via microphotogra-
phy and performed immediately after 24 h injury. Differences
were analyzed using NIH Image 1.6 program (Wayne Rasband).
Boyden chamber cell migration assay was performed using
transwell chambers with fibronectin (Sigma)-coated 8-mm-pore-
size polycarbonate membranes (BD Biosciences). Preconfluent
VSMCs treated in the same way were then suspended in DMEM-
0.5% FBS to a concentration of 4610
5 cells/mL. Different fatty
acids or serum free DMEM (0.6 mL) were added to the lower
compartment. A 0.1-mL cell suspension (final concentration,
4610
4 cells/well; diameter, 6.5 mm) was added to the upper
compartment, and cells were then incubated at 37uC (95% air-5%
CO2). 6 h later, nonmigrated cells were removed with a cotton
swab, and the migrated cells were fixed with paraformal-dehyde
for 30 min and stained with crystal violet. Cell migration was
quantified by blind counting of the migrated cells on the lower
surface of the membrane of 5 fields per chamber under
microscope.
RNA analysis
To examine the expression level of PGC-1a in rat VSMCs, total
RNA was isolated using RNeasy kit (Qiagen, Hilden, Germany).
One microgram of RNA was reverse-transcribed into cDNA with
oligo (dT)18 primers and AMV reverse transcriptase (Gibco
invitrogen, Carlsbad, CA, USA) at 42uC for 1 h. Quantitative
PCR was performed with the ABI Prism 7000 sequence detection
system (Applied Biosystem, Foster City, CA) with Tagman probes
(Shanghai Shinegene Molecular Biotechnology Co., LTD.), and
threshold cycle numbers were obtained using ABI Prism 7000
SDS software version 1.0. Amplification conditions were: one cycle
of 95uC for 5 min followed by 40 cycles of 95uC for 30 s, 60uC for
1 min, and final one cycle of 72uC for 2 min. Sequences of
quantitative PCR primers and probes were as follows: rat PGC-1a,
59-AGGTCCCCAGGCAGTAGAT-39 (sense), 59-CGTGCTCA-
TTGGCTTCATA-39 (antisense), 59FAM+ATGAATCAAGC-
CACTACAGACACC+TAMRA39 (probe); rat b-actin, 59-AGG-
GAAATCGTGCGTGAC-39 (sense), 59-CGCTCATTGCCGA-
TAGTG-39 (antisense); 59 FAM+CTGTGCTATGTTGCCCT-
AGACTTC+TAMRA39 (probe).
Western blot analysis
To obtain total proteins, VSMCs were lysesed in a buffer
containing 10 mmol/L HEPES (pH 7.9), 1.5 mmol/L MgCl2,
10 mmol/L KCl, and 0.5% NP-40, and cell lysates were
centrifuged at 13000 g for 5 min. Supernatants were collected as
cytosolic extracts for western blot. Nuclear extracts were isolated
according to Andrews et al [50]. Protein concentration was
determined colorimetrically with BCA method (Pierce, Rockford,
USA). Nuclear extracts containing 200 mg nuclear proteins were
applied to 10% SDS-PAGE gel electrophoresis for PGC-1a
detection, and rabbit polyclonal PGC-1a antibody (Santa Cruz
Biotechnology, Santa Cruz, USA) was used as primary antibody.
Samples containing 30 mg total proteins were applied to 15%
SDS-PAGE gel electrophoresis for phosphorylated ERK1/2
detection. Phospho-specific mouse anti-human ERK1/2 antibody
(Santa Cruz Biotechnology, Santa Cruz, USA), which detected
only phosphorylated activated forms, and mouse anti-human
ERK antibody (Santa Cruz) were used as primary antibody. After
incubation with primary antibodies for 2 h and washing,
membranes were incubated with corresponding horseradish
peroxidase (HRP) conjugated secondary antibody, and detected
with a chemiluminescent detection system (NEN, Boston, USA).
Statistical analysis
All results are expressed as means6SEM. Data were analyzed
using a one-way ANOVA followed by Fisher’s LSD post-hoc test.
Calculations were performed using SPSS/Windows version 12.5S
PGC-1a’s Role in VSMC Growth
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was taken as statistically significant.
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